Myocarditis Treatment Trial
Launched by UNIVERSITY OF UTAH · Oct 27, 1999
Trial Information
Current as of July 03, 2025
Completed
Keywords
ClinConnect Summary
BACKGROUND:
Heart failure due to myocarditis can be a devastating illness. At the same time, immunosuppressive therapy is associated with considerable risks of untoward side effects. Clinicians did not know whether, under what circumstances, or in what form, this hazardous treatment should be used in such critically ill patients. In addition, if immunosuppressive therapy was of benefit, then endomyocardial biopsy in patients suspected of having myocarditis was a justified procedure. The trial also provided information concerning the side effects of immuno-suppressive therapy in such patien...
Gender
ALL
Eligibility criteria
- • Men and women, 18 years of age or older, with left ventricular failure and biopsy-documented myocarditis.
About University Of Utah
The University of Utah is a prestigious research institution known for its commitment to advancing medical knowledge and improving patient care through innovative clinical trials. With a robust infrastructure that supports a wide range of biomedical research initiatives, the university leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical studies. By fostering collaboration among researchers, clinicians, and community partners, the University of Utah aims to translate scientific discoveries into effective therapies and interventions, ultimately enhancing health outcomes and contributing to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Jay Mason
University of Utah
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials